特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
959706

BERCOLAGENE TELSERPAVEC (KB103):新興医薬品の考察・市場予測 (2030年)

BERCOLAGENE TELSERPAVEC (KB103)- Emerging Drug Insight and Market Forecast - 2030

出版日: | 発行: DelveInsight Business Research LLP | ページ情報: 英文 50 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.45円
BERCOLAGENE TELSERPAVEC (KB103):新興医薬品の考察・市場予測 (2030年)
出版日: 2020年09月08日
発行: DelveInsight Business Research LLP
ページ情報: 英文 50 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

B-VEC は Krystal の主要製品候補であり、遺伝子治療を使用して、栄養障害型表皮水疱症(DEB)の治療を目指しています。これは、皮膚のコラーゲンの欠如によって引き起こされる不治の皮膚水疱疾患です。 B-VECは、Krystal の STAR-Dプラットフォームを使用して、機能的なヒトCOL7A1遺伝子を患者の分裂および非分裂皮膚細胞に直接送達する、複製欠陥のある非統合型ウイルスベクターです。 Krystal の HSV-1 は、他のウイルスベクターよりも効率的に皮膚細胞に侵入できる独自のベクターです。その高いペイロード容量は、それが大きなまたは複数の遺伝子に対応することを可能にし、その低い免疫原性は、それを皮膚への直接および反復送達に適した選択にします。

当レポートでは、米国、欧州5ヶ国(ドイツ、フランス、イタリア、スペイン、英国)、および日本の7つの主要市場における BERCOLAGENE TELSERPAVEC (KB103) について詳細に説明し (作用機序、投与量、合成経路、規制のマイルストーンを含む研究開発活動、およびその他の開発活動)、SWOT分析、市場の競合企業、およびその他の新たな治療法を含む将来の市場評価を提供しています。

目次

第1章 医薬品の概要

  • 製品の詳細
  • 作用機序
  • 投薬と管理
  • 研究開発活動
    • 臨床開発
    • 安全性と有効性
  • その他の開発活動

第2章 市場評価

  • 主要7ヶ国市場分析
  • 米国市場
  • ドイツ市場
  • フランス市場
  • イタリア市場
  • スペイン市場
  • 英国市場
  • 日本市場

第3章 SWOT分析

第4章 アナリストの見解

第5章 市場の競合企業

第6章 その他の新しい治療法

第7章 付録

第8章 レポート購入オプション

図表

List of Tables

  • Table 1 BERCOLAGENE TELSERPAVEC (KB103), Description
  • Table 2 BERCOLAGENE TELSERPAVEC (KB103), Clinical Trial Description
  • Table 3 BERCOLAGENE TELSERPAVEC (KB103), 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of BERCOLAGENE TELSERPAVEC (KB103)
  • Figure 2 Patent Details, BERCOLAGENE TELSERPAVEC (KB103)
  • Figure 3 BERCOLAGENE TELSERPAVEC (KB103), 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 BERCOLAGENE TELSERPAVEC (KB103), US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 BERCOLAGENE TELSERPAVEC (KB103), EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 BERCOLAGENE TELSERPAVEC (KB103), Japan Market Size from 2020 to 2030 (in Millions USD)
目次
Product Code: DIDM0057

"BERCOLAGENE TELSERPAVEC (KB103)- Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Epidermolysis bullosa in 7 Major Markets. A detailed picture of the BERCOLAGENE TELSERPAVEC (KB103) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary:

B-VEC is Krystal's lead product candidate that seeks to use gene therapy to treat dystrophic epidermolysis bullosa, or DEB, an incurable skin blistering condition caused by a lack of collagen in the skin. B-VEC is a replication-defective, non-integrating viral vector employing Krystal's STAR-D platform to deliver functional human COL7A1 genes directly to the patients' dividing and non-dividing skin cells. Krystal's HSV-1 is a proprietary vector that can penetrate skin cells more efficiently than other viral vectors. Its high payload capacity allows it to accommodate large or multiple genes and its low immunogenicity makes it a suitable choice for direct and repeat delivery to the skin.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around BERCOLAGENE TELSERPAVEC (KB103).
  • The report contains forecasted sales for BERCOLAGENE TELSERPAVEC (KB103) till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Epidermolysis bullosa.
  • The report also features the SWOT analysis with analyst insights and key findings of BERCOLAGENE TELSERPAVEC (KB103).

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

BERCOLAGENE TELSERPAVEC (KB103) Analytical Perspective by DelveInsight

  • In-depth BERCOLAGENE TELSERPAVEC (KB103) Market Assessment

This report provides a detailed market assessment of BERCOLAGENE TELSERPAVEC (KB103) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • BERCOLAGENE TELSERPAVEC (KB103) Clinical Assessment

The report provides the clinical trials information of BERCOLAGENE TELSERPAVEC (KB103) covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Epidermolysis bullosa is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence BERCOLAGENE TELSERPAVEC (KB103) dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Epidermolysis bullosa are giving market competition to BERCOLAGENE TELSERPAVEC (KB103) and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of BERCOLAGENE TELSERPAVEC (KB103).
  • Our in-depth analysis of the forecasted sales data of BERCOLAGENE TELSERPAVEC (KB103) from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the BERCOLAGENE TELSERPAVEC (KB103).

Key Questions:

  • Which company is developing BERCOLAGENE TELSERPAVEC (KB103) along with the phase of the clinical study?
  • What is the technology utilized in the development of BERCOLAGENE TELSERPAVEC (KB103)?
  • What is the product type, route of administration and mechanism of action of BERCOLAGENE TELSERPAVEC (KB103)?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the BERCOLAGENE TELSERPAVEC (KB103) development?
  • What are the key designations that have been granted to BERCOLAGENE TELSERPAVEC (KB103)?
  • What is the forecasted market scenario of BERCOLAGENE TELSERPAVEC (KB103)?
  • What is the history of BERCOLAGENE TELSERPAVEC (KB103) and what is its future?
  • What is the forecasted sales of BERCOLAGENE TELSERPAVEC (KB103) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to BERCOLAGENE TELSERPAVEC (KB103)?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.